Unlocking cellular profiling and target discovery with epitope resolution
Investors 1
Mentions in press and media 3
| Date | Title | Description |
| 06.04.2026 | Stipple Bio Emerges From Stealth with $100M Series A |
CAMBRIDGE, MA, Stipple Bio, a private biotechnology company harnessing epitope-level precision to create targeted cancer therapies, announced the close of a $100 million Series A financing.
>> Click here for more funding data on Stip... |
| 06.04.2026 | Stipple Bio Raises $100M in Series A Financing | Stipple Bio, Inc., a Cambridge, MA-based biotechnology company leveraging epitope-level precision to create targeted cancer therapies, closed a $100m Series A financing.
The round was co-led by RA Capital, a16z Bio+Health and Nextech Invest... |
| - | Stipple Bio | “Unlocking cellular profiling and target discovery with epitope resolution” |
Reviews 0